| (Values in U.S. Thousands) | Jun, 2022 | Mar, 2022 | Dec, 2021 | Sep, 2021 | Jun, 2021 |
| Sales | 10,540 | 10,430 | 12,210 | 13,310 | 16,060 |
| Sales Growth | +1.05% | -14.58% | -8.26% | -17.12% | -52.96% |
| Net Income | 2,460 | 0 | 3,770 | -2,260 | 3,730 |
| Net Income Growth | unch | -100.00% | +266.81% | -160.59% | -74.13% |
LA Jolla Pharma
(LJPC)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
LA JOLLA PHARMACEUTICAL CO. is engaged in the research and development of therapeutic products for the treatment of autoimmune and inflammatory diseases.
Fiscal Year End Date: 12/31